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Abstract 
Background: Outcome expectancies are a key cognitive construct in the etiology, assessment 
and treatment of Substance Use Disorders. There is a research and clinical need for a 
cannabis expectancy measure validated in a clinical sample of cannabis users. Method: The 
Cannabis Expectancy Questionnaire (CEQ) was subjected to exploratory (n = 501, mean age 
27.45, 78% male) and confirmatory (n = 505, mean age 27.69, 78% male) factor analysis in 
two separate samples of cannabis users attending an outpatient cannabis treatment program. 
Weekly cannabis consumption was clinically assessed and patients completed the Severity of 
Dependence Scale- Cannabis (SDS-C) and the General Health Questionnaire (GHQ-28). 
Results: Two factors representing Negative Cannabis Expectancies and Positive Cannabis 
Expectancies were identified. These provided a robust statistical and conceptual fit for the 
data. Internal reliabilities were high. Negative expectancies were associated with greater 
dependence severity (as measured by the SDS) and positive expectancies with higher 
consumption. The interaction of positive and negative expectancies was consistently 
significantly associated with self-reported functioning across all four GHQ-28 scales 
(Somatic Concerns, Anxiety, Social Dysfunction and Depression). Specifically, within the 
context of high positive cannabis expectancy, higher negative expectancy was predictive of 
more impaired functioning. By contrast, within the context of low positive cannabis 
expectancy, higher negative expectancy was predictive of better functioning. Conclusions: 
The CEQ is the first cannabis expectancy measure to be validated in a sample of cannabis 
users in treatment. Negative and positive cannabis expectancy domains were uniquely 
associated with consumption, dependence severity and self-reported mental health 
functioning.  
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 1. Introduction 
Social Learning Theory (SLT, Bandura, 1969; 1977; 1986) provides a comprehensive 
model of motivation for human thought and behavior. Outcome expectancies are central to 
SLT. These expectancies relate to the anticipated effects of participating in desirable or 
undesirable behavior and are one of the most widely studied cognitive constructs in 
Substance Use Disorders (Leonard and Blane, 1999; Young and Oei, 1993). In addictive 
behavior, outcome expectancy research has focused on alcohol use (Jones et al., 2001). A 
number of instruments have been developed to measure alcohol outcome expectancies. 
Widely used instruments include the Alcohol Expectancy Questionnaire (AEQ, Brown et al., 
1980; 1987) and the Drinking Expectancy Questionnaire (DEQ, Young and Knight, 1989; 
Young and Oei, 1996). Salient alcohol expectancies are consistently associated with high 
alcohol consumption and dependence severity in both non-clinical (e.g., Connor et al., 2000; 
Young et al., 2006) and clinical populations (e.g., Connor et al., 2007), and relapse following 
treatment (e.g., Brown, 1985). 
Consistent with alcohol expectancy research, individuals who hold elevated cannabis 
expectancies are at a greater risk of excess cannabis use and cannabis-related problems. The 
most commonly used cannabis outcome expectancy instrument is The Marijuana Effect 
Expectancy Questionnaire (MEEQ; Schafer and Brown, 1991). Based on interviews with 
community volunteers, some of whom had used cannabis previously, Schafer and Brown 
(1991) developed the 70-item MEEQ. Scale validation involved randomly subjecting a 
sample of 704 college students (mean age 19.23 years) that had completed the MEEQ to 
exploratory and confirmatory factor analysis (both using Principle Components Analysis). 
This resulted in a multi-dimensional scale that included negative (N) and positive (P) 
expectancy factors: Cognitive and Behavioral Impairment (N), Relaxation and Tension 
reduction (P), Social and Sexual Facilitation (P), Perceptual and Cognitive Enhancement 
(P), Global Negative Effects (N), and Craving and Physical Effects (P). The MEEQ 
discriminated between non-users and users. Non-use was associated with stronger negative 
expectancies whereas frequent use was associated with positive expectancies. Similarly, 
Galen and Henderson (1999) using a sample of 149 male polysubstance and alcohol users 
seeking treatment, found that higher negative expectancies and lower positive expectancies 
on the MEEQ were associated with cannabis abstinence. Construct validity of the MEEQ 
using a sample of 114 community and 165 youth in a non-cannabis specific substance misuse 
treatment program was undertaken using confirmatory factor analysis by Aarons et al. (2001). 
This study provided support for the original factor structure and additionally provided two 
higher order composite scales; Negative Effects and Positive Effects. Consistent with previous 
findings, high negative cannabis expectancies were most protective of cannabis use. Due to 
sample size restrictions, this study evaluated each factor separately and therefore was unable 
test the overall factor structure of the measure. 
Three additional cannabis expectancy scales have been developed in non-adult 
populations; the Marijuana Expectancy Inventory for Children and Adolescents (MEICA, 
Linkovich-Kyle and Dunn, 2001), the Memory Model-Based Marijuana Expectancy 
Questionnaire (MMBMEQ; Alfonso and Dunn, 2007) and the Adolescent Cannabis 
Expectancies Questionnaire (ACEQ; Willner, 2001). The MEICA and MMBMEQ 
expectancy scales were developed by asking cannabis naive and former or current cannabis 
users to generate stimulus words. No further scale validation was undertaken. The ACEQ was 
developed by modifying the adolescent version of the Alcohol Expectancy Questionnaire 
(AEQ, Brown et al., 1980; 1987), effectively replacing „drinking‟ or „drinking alcohol‟ with 
„cannabis‟ or „smoking cannabis‟. Ten percent of the sample reported a history of cannabis 
use (2.5% weekly use). Validation of the scale included exploratory factor analysis which 
yielded two factors measuring positive and negative cannabis expectancies. Consistent with 
previous studies, cannabis use was more strongly associated with positive cannabis 
expectancies and negative expectancies, never-users. Concurrent validity testing confirmed 
cannabis expectancies were also related to problem drug use (measured by the Assessment of 
Substance Misuse in Adolescents [ASMA] scale; Wilner, 2000).  
Central to expectancy theory is the concept of automatic (or implicit) activation. This 
process involves memory networks being activated by actual or imagined cues or stimuli, 
interpreted through individual expectancy beliefs (Goldman, et al., 1999). In alcohol research, 
these implicit cognitions have been associated with drinking behavior (eg. Goldman, et al., 
1999; Read, et al., 2009). Linkovich-Kyle and Dunn (2001), and Alfonso and Dunn (2007) 
reported that non-cannabis users were more likely to activate negative expectancy stimulus 
words and cannabis users, positive expectancies stimulus words. Psychometric scales have 
consistently identified that both positive and negative cannabis expectancies are evident in 
non-clinical samples, typically consisting of light users and non-users. While recognizing that 
vicarious learning contributes to the development of substance expectancies and associated 
memory networks (e.g., Christiansen et al., 1989; Goldman, et al., 1999), there is less 
opportunity for non or light -users to accurately report the anticipated effects of cannabis due 
to the illicit nature of the substance. This sampling approach is not optimal when developing 
a measure intended for clinical application.  
A psychometrically robust cannabis expectancy measure validated on a sample of 
cannabis users has yet to be developed for clinical use. Scale validation should include both 
exploratory factor analysis and confirmatory factor analysis using structural equation 
modeling (Tabachnick, and Fidell, 2007). Concurrent validity testing needs to extend beyond 
„use‟ categories to important clinical markers of cannabis dependence severity, cannabis 
consumption and broader assessments of mental health functioning.  
 2. Methods 
 
2.1. Participants 
  consecutive individuals (n=1083) were referred by the Queensland Illicit Drug 
Diversion Initiative (QIDDI) for assessment at a public hospital alcohol and drug service.. 
QIDDI is a police diversion program for individuals charged with cannabis-related offences. 
It involves a two-hour assessment of substance use and psychosocial functioning that 
incorporates motivational interviewing. Over the course of recruitment, 14.5% of diverted 
individuals did not attend treatment. Of those that presented for the treatment session, all 
completed initial assessments and program content. Assessments were conducted by Masters 
and PhD qualified clinical psychologists (with between 2 and 25 years alcohol and drug 
treatment experience; M = 10.5 years).  
The mean age of the sample was 27.86 years (S.D. = 8.48). There were 830 males and 
253 females. The majority of participants were born in Australia (888; 82.0%) or New 
Zealand (80; 7.4%), with 41 (3.8%) identifying themselves as Indigenous. To obtain 
exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) samples, the data 
was randomly split into two data sets.  
 
2.2. Measures 
 2.2.1. Demographics.  Information relating to gender, age, marital status, level of 
education, employment, and country of origin were collected. 
 2.2.2. Cannabis Expectancy Questionnaire (CEQ) (Young and Kavanagh, 1997). The 
CEQ is a 60-item questionnaire assessing positive and negative cannabis use outcome 
expectancies. Items included a five-point, Likert-style response format (1 = Strongly 
Disagree to 5 = Strongly Agree). Items (n =92) were generated from interviews with 27 
cannabis users using edited transcripts of responses to questions a) How does cannabis affect 
you? B) How do you behave when smoking and c) How does cannabis change your 
emotions? These individuals (14 males, 13 females) were not part of the original study 
sample and reported an average frequency of use of four occasions per week. One third of the 
sample (n =9) met DSM criteria for cannabis dependence. Selection criteria used to refine 
and select items were based on those used to develop the Drinking Expectancy Questionnaire 
(Young & Knight, 1989). The scale has undergone preliminary validation (Lyons, 2003; 
Hides et al., 2008) but no factor analytic studies have been published. 
 2.2.3. Severity of Dependence Scale- Cannabis (SDS-C) (Gossop et al., 1995). The 
SDS is a five-item scale which measures the degree of dependence experienced by people 
who use different types of substances. The SDS is sensitive to severity of cannabis 
dependence (Swift et al., 2000).
 
Using Australian normative data, the SDS cut-off for likely 
cannabis dependence is two (Swift et al., 1998). 
 2.2.4. Cannabis Consumption was clinically assessed using a retrospective diary 
approach over the past week. For the purposes of this study, „joints‟ (cannabis cigarette) were 
quantified as .25 grams of cannabis and „cones‟ (use of „bong‟), .10 grams of cannabis. 
 2.2.5. General Health Questionnaire- 28 (GHQ-28)
 
(Goldberg and Williams, 1991). 
The GHQ-28 is a 28-item self-report measure which identifies short-term changes in health 
perception. It has four sub-scales (i) Somatic Symptoms, (ii) Anxiety, (iii) Social Dysfunction 
and (iv) Depression (Goldberg and Williams, 1991). The GHQ-28 is a widely used measure 
of psychological health and has strong psychometric properties (Goldberg and Williams, 
1991; Goldberg et al., 1997; Werneke et. al., 2000). 
 
2.3. Procedure 
 Approval was obtained from the hospital human ethics committee to access de-
identified, retrospective assessment data for patients participating in the treatment program. 
As part of the assessment protocol, individuals participating in the QIDDI program 
completed a questionnaire package which included the CEQ, GHQ-28 and SDS-C.  
 
3. Study 1: Exploratory Factor Analysis of the Cannabis Expectancy Questionnaire 
(CEQ) 
Of the original sample (540 EFA), 39 (7.2%) participants did not respond to at least 
50% of CEQ items and were excluded, leaving 501 cases for further analysis. Non-
responders did not differ from responders in age or weekly amount of cannabis. There were 
significantly more females in the non-responder group (χ2[1] = 5.38. p = .02). Descriptive 
data is presented in Table 1. Approximately 61% of participants met the SDS dependence 
cut-off (≥ 2; Swift et.al., 1998).  
 
_______________ 
Insert Table 1 here 
_______________ 
 
An initial principal components analysis (PCA) with oblique rotation was used to 
estimate number of principal components. The Kaiser-Meyer-Olkin (KMO) measure of 
sampling adequacy was .93, indicating suitable factorability of correlation matrices. 
Eleven components with eigenvalues > 1 were identified. Examination of the scree 
plot suggested the presence of three principal components. However, a two-component PCA 
provided the optimal solution in terms of percentage of variance explained, number of items 
per factor, and absence of cross-loadings. Extracted components were significantly 
correlated. However, as the magnitude of correlation was low (e.g., r = .22), orthogonal 
rotation was retained.  
In total, the two extracted components accounted for 36.66% of the variance. Seven 
items were removed because of high cross-loadings (≥ .30) or low communalities (< .10). 
Eight additional items with markedly skewed distributions were also excludedThe PCAs 
were then re-run on the remaining 45 items. The result of these analyses again suggested a 
two-factor solution with orthogonal rotation was optimal, accounting for 39.13% of the 
variance. Item loadings are presented in Table 2. The first component was labeled Negative 
Cannabis Expectancy (27 items) and the second labeled Positive Cannabis Expectancy (18 
items). The two components had high internal consistencies. 
 
_______________ 
Insert Table 2 here 
_______________ 
 
4. Study 2: Confirmatory Factor Analysis of the Cannabis Expectancy Questionnaire 
(CEQ) 
Of the original 543 CFA participants, 37 did not respond to at least 50% of CEQ 
items, and were excluded from further analyses. One multivariate outlier was also 
subsequently excluded. Non-responders did not differ from responders in age, gender, or 
average weekly cannabis use.Descriptive statistics for the sample are displayed in Table 3. 
Approximately 50% of participants met SDS dependence criteria.  
Cronbach‟s α coefficients suggested both the Negative Cannabis Expectancy (α = .93) 
and Positive Cannabis Expectancy (α = .89) scales had strong internal reliability. Males (M = 
63.32, S.D. = 16.05) did not differ from females (M = 63.58, S.D. = 17.25) in negative 
cannabis expectancy scores, t (171.71) = -0.14, p = .89. Similarly, males (M = 50.19, S.D. = 
10.78) did not differ from females (M = 49.90, S.D. = 10.65) in positive cannabis expectancy, 
t (504) = 0.25, p = .80. 
_______________ 
Insert Table 3 here 
_______________ 
 
 
4.1. Model Estimation and Evaluation 
Confirmatory factor analysis (CFA) was conducted in AMOS (6.0) using maximum 
likelihood estimation. Stringent criteria were adopted to ensure a rigorous evaluation of 
model fit, recognizing it is difficult to set specific criteria for the evaluation of model fit in 
CFA as fit indices are not equally effective across different conditions (Hu and Bentler, 1999; 
Marsh et al., 2004). A χ2 test was selected as a statistical test of model fit (α = .05). However, 
this test can be overly sensitive to trivial deviations in model fit in large samples (Ho, 2006). 
Therefore, the comparative fit index (CFI), root mean-square error of approximation 
(RMSEA), and standardized root mean-square residual (SRMR) were also used to evaluate 
model fit (Bentler, 2007). The following cut-offs were used for „good‟ fit: CFI ≥ .95; SRMR 
≤ .08 (Hu and Bentler, 1999). RMSEA values < .05  represent good model fit, values 0.05 - 
0.08 are considered acceptable, 0.08 - 0.10 mediocre, > .10 indicate poor fit” (Ho, 2006).  
The Akaike Information Criterion (AIC) was also examined to assist model 
evaluation/comparison (Akaike, 1987). The AIC has no conventional cut-off. Smaller values 
indicate a model is better-fitting and more parsimonious. In addition to reporting SRMR, 
Bentler (2007) recommended reporting the largest several standardized residual covariances. 
In a good-fitting model, none/few of these values should exceed 2.58 (p < .01).  
 
4.2. Confirmatory Factor Analysis (CFA) 
Based on the results of exploratory factor analysis (Study 1), the hypothesized 
measurement model included negative cannabis expectancy as a latent variable with 27 items 
as indicators, and positive cannabis expectancy as a latent variable with 18 items as 
indicators. Latent variables allowed to covary. The assumption of multivariate normality was 
violated and the extent of non-normality preclude the use of maximum likelihood estimation 
(Mardia‟s Normalized coefficient = 82.23, p < .001). This was likely due to the cumulative 
effect of specifying such a large number of variables (45 items) in the model; many with 
slightly non-normal distributions (Goldman et al., 1997).  
Item parceling was employed to address the severity of multivariate non-normality 
(Alhija and Wisenbaker, 2006). Item parcels were created by assigning individual CEQ items 
to parcels on an alternating basis (e.g., item 1 to parcel 1, item 2 to parcel 2, and so on) and 
tallying them (Alhija and Wisenbaker, 2006). This method of parceling is similar to that used 
by Goldman et al. (1997) with the Alcohol Expectancy Questionnaire. For negative cannabis 
expectancy, this resulted in three parcels of five items and two parcels of seven items. For 
positive cannabis expectancy, this resulted in two parcels of five items and two parcels of 
four items. One multivariate outlier was detected, which did affect model fit and was 
removed. 
The hypothesized measurement model provided an adequate fit of the data (see Table 
4, Model 1). Internal reliabilities were .93 and.89 for Positive and Negative Expectancies, 
respectively. The largest standardized residual covariance was between positive expectancy 
item parcel 4 and negative expectancy item parcel 1 (-4.44), and was the only value to exceed 
2.58. As shown in Figure 1, the two latent factors accounted for a large amount of variance in 
their respective indicators (R
2
 = .63 - .80). Furthermore, there was a non-significant trend for 
the two latent factors to covary (r = .13, p = .05).  
The hypothesized model was compared to an alternative one-factor expectancy model 
in which all item parcels served as indicators of a single cannabis expectancy factor. This 
model showed a poor fit to the data (see Table 4, Model 2).  
 
_______________ 
Insert Table 4 here 
_______________ 
 
_______________ 
Insert Figure 1 here 
_______________ 
 
Given that sex differences have been observed in previous cannabis expectancy research 
(e.g., Gaher and Simons, 2007), the influence of gender on parameter estimates and model fit 
was also examined in a multi-group CFA. The hypothesized two-factor multi-group model 
was also an adequate fit for the data (see Table 4, Model 3). Lastly, a multi-group CFA was 
conducted on a non-hypothesized alternative model specifying one expectancy factor. This 
model showed a poor fit to the data (see Table 4, Model 4).  
 
 
4.3. Prediction of cannabis use and dependence 
 Of the total sample used in the CFA, 81 participants did not provide data regarding 
their average weekly cannabis use (grams). These participants did not differ in their positive 
or negative cannabis expectancies from those who did provide data (p < .05). To explore the 
predictive role of expectancies, a hierarchical multiple regression, controlling for age and sex, 
was conducted with average weekly cannabis use as the dependent variable. As shown in 
Table 5 only positive expectancy contributed unique variance to prediction (sr
2
 = .03). The 
interaction between negative and positive expectancy was not significant. 
 To investigate the prediction of cannabis dependence, a second hierarchical multiple 
regression was conducted with SDS total score as the dependent variable. Overall, the model 
accounted for approximately 9% variance in SDS scores, F (5, 325) = 6.24, p < .001. As 
shown in Table 5, only negative expectancy contributed significant unique variance to 
prediction in the final model (sr
2
 = .06).  
Applying the SDS dependence cut-off (Swift et al., 1998), dependent participants (M 
= 66.16, S.D. = 15.68) reported significantly higher scores than non-dependent participants 
(M = 58.97, S.D. = 14.45) on the negative expectancy factor, t (329) = 4.16, p < .001. There 
was also a significant difference between dependent (M = 51.21, S.D. = 10.52) and non-
dependent participants (M = 48.58, S.D. = 11.41) on positive expectancy, t (329) = 2.14, p = 
.03).  
 
_______________ 
Insert Table 5 here 
_______________ 
 
 
4.4. Prediction of Health Status 
 To investigate whether the CEQ scales could predict variance in different health 
domains, after controlling for weekly cannabis use and severity of dependence, a series of 
regression analyses were conducted on the subscales of the GHQ. The model also examined 
how unique interactions of positive and negative cannabis expectancies may either act as a 
risk or protective factor for self-reported psychological health, above that already known by 
the factors operating independently (see Table 6). The regression model for somatic 
symptoms was significant, F (5, 325) = 3.17, p = .01, with negative expectancy (sr
2
 = .012) 
and the positive-negative expectancy interaction (sr
2
 = .024) emerging as unique predictors.  
Similarly, the regression model predicting GHQ anxiety was significant, F (5, 325) = 3.36, p 
= .01, with the positive-negative expectancy interaction (sr
2
 = .020) emerging as the only 
unique predictor (see Table 6).  The regression model predicting GHQ social dysfunction was 
significant, F (5, 324) = 6.78, p < .001, with negative expectancy (sr
2
 = .017) and the 
positive-negative expectancy interaction (sr
2
 = .036) emerging as unique predictors (see 
Table 6).  GHQ depression was also statistically significant, F (5, 324) = 5.86, p < .001, with 
positive expectancy (sr
2
 = .046) and the positive-negative expectancy interaction (sr
2
 = .052) 
emerging as unique predictors.  
Simple slopes analysis was used to interpret the significant interactions across all 
GHQ subscales. In all four GHQ subscales, participants with low positive expectancy/high 
negative expectancy reported less psychological distress. High positive expectancy/high 
negative expectancy was associated with more psychological distress. 
 
 
5. Discussion 
This paper reports on the development and validation of the Cannabis Expectancy 
Questionnaire (CEQ) in a sample of cannabis users referred for treatment. The findings 
confirmed a two-factor structure, represented by Negative Cannabis Expectancies and 
Positive Cannabis Expectancies. Model measurement and structural invariance across gender 
indicated an absence of sex differences. These findings are consistent with other cannabis 
expectancy studies, largely conducted in non-clinical samples, reporting negative and positive 
cannabis expectancy factors (e.g., Aarons et al., 2001; Wilner, 2001). The present scale has 
an advantage over other scales given the rigor of the psychometric development process and 
confirmatory factor analysis in a clinical sample. The identified factors were conceptually 
and statistically unique (i.e., only 1.7% shared variance) with each differentially predicting 
key indices of cannabis-related problems. Positive cannabis expectancies were associated 
with greater weekly consumption and negative expectancy, higher dependence severity. The 
interaction of positive and negative expectancies was also associated with all four GHQ-28 
scales of somatic symptoms, anxiety, social dysfunction and depression. This clinical 
information adds to the existing body of work which to date has largely examined risk of use. 
The contribution of both negative and positive expectancies to cannabis use (3%) and 
dependence severity (6%) are generally consistent with alcohol expectancy studies that also 
control for known factors associated with problem drinking (eg. age, gender, attitudes), 
however some alcohol expectancy studies report variances of 25% or more (see Jones, et al, 
2001 for a review). There are no comparable published data to assess if the CEQ variance 
towards cannabis use and dependence severity was consistent with previous cannabis 
expectancy studies. The conservative statistical model presented in this study recognizes that 
there are many factors, both measured and unmeasured, that contribute to cannabis 
consumption. Cannabis expectancies, as measured by the CEQ, offered novel variance in our 
understanding of the etiology of cannabis use and related problems.  
Research in non-clinical (Schafer and Brown, 1991) and non-cannabis specific 
substance use populations (Aarons et al., 2001; Galen and Henderson, 1999) has identified 
negative cannabis expectancies as being protective. The results of the current study identify 
that in a cannabis using sample, negative expectancies are also a marker of dependence 
severity. Gaher and Simons (2007), using the Marijuana Effect Expectancies Questionnaire 
(MEEQ, Aarons et al., 2001) in a non-clinical sample, also found negative expectancies (but 
not positive expectancies) were associated with Marijuana Problem Index (MPI, Johnson and 
White, 1989), a proxy measure for cannabis dependence severity. These results are consistent 
with a substantial body of work that reports more extensive drinking experience is associated 
with stronger endorsement of negative alcohol expectancies (eg. Jones and McMahon, 1994; 
1996).  Further prospective studies are required to confirm if impairment is likely to be 
reported as a negative expectancy as cannabis dependence severity increases.  
Positive expectances were more strongly associated with heavy cannabis 
consumption, but not dependence severity. Within a cannabis-using population, positive 
expectancies may identify individuals currently using cannabis but registering at the less 
severe end of the dependence continuum. Previous non-clinical cannabis expectancy studies 
have identified that positive expectancies are associated with risk of use (Schafer and Brown, 
1991; Willner, 2001). Where consumption has been measured, a significant relationship with 
the MEEQ total scale, (combining positive and negative expectancies) has been identified 
(Barnwell and Earlywine, 2006). The current study further highlights positive cannabis 
expectancies as an important clinical marker for cannabis consumption in a similar manner to 
positive alcohol expectancies being associated with heavier use in non-clinical (Young et al., 
2006) and clinical (e.g., Kline, 1990) drinking populations.  
Cannabis users have significantly more impaired functioning on GHQ-28 scores of 
somatic concern, anxiety, social dysfunction and depression compared to the general 
population (Feeney et al., 2005). Negative and positive cannabis expectancies have also been 
independently linked with anxiety (Buckner and Schmidt, 2008; 2009). In the current study, 
the strongest associations with impaired psychological functioning resulted from the unique 
interaction of high negative expectancies and high positive outcomes expectancies. 
Interestingly, the nature of the association between negative expectancy and functioning 
depended on participants‟ level of positive expectancy. For individuals with high positive 
cannabis expectancy, higher negative expectancy was associated with poorer psychological 
health. On the other hand, for individuals with low positive cannabis expectancy, higher 
negative expectancy was associated with better psychological health. This finding held across 
all four GHQ-28 sub-scales, even after controlling for cannabis consumption and dependence 
severity. Anxiety and depression are common comorbid conditions associated with cannabis 
use (Moore et al., 2007) and in this treatment sample were markedly impaired. In addition to 
utility as prognostic markers for cannabis use and dependence, the interaction of positive and 
negative cannabis expectancies may reflect the complex etiology associated with comorbid 
cannabis dependence presentations. 
 Targeting expectancies by challenging anticipated positive outcomes to reduce 
consumption has been successful in „at risk‟ moderate-to-heavy drinking populations (e.g., 
Darkes and Goldman, 1993; Lau-Barraoc and Dunn, 2008; Wiers and Kummeling, 2004; 
Wood et al., 2007). This approach systematically identifies and modifies alcohol expectancies 
through challenging drinkers learnt positive expectation of the anticipated outcomes of 
alcohol use. In addition to Motivational Interviewing, „Alcohol Expectancy Challenges‟ are 
identified by the National Institute of Alcohol Abuse and Alcoholism (NIAA) as a key (Tier 
1) preventive strategy for college drinking (Goldman, 2002; 
http://www.collegedrinkingprevention.gov/StatsSummaries/4tier.aspx  accessed 21 
September 2010). As an adjunct to existing cannabis assessment tools, measuring positive 
and negative expectancies through the CEQ, when compared to normative data (see Table 3), 
may afford a more strategic clinical approach to patient feedback, treatment and outcome 
assessment. Fewer studies have prospectively examined behavior change through 
modification of cannabis expectancies. Although Newton et al. (2009) demonstrated that a 
computerized prevention course targeting cannabis and alcohol beliefs reduced cannabis and 
alcohol consumption in the experimental group at six months post intervention, no changes 
were observed in substance-related expectancies and attitudes.  Based on these preliminary 
cross-sectional data, treatment strategies that target and challenge high positive expectancy 
may not only benefit consumption, but also mental health. Further prospective work in the 
context of a controlled design is required to confirm this. 
The current study has some limitations. The sample of police referred cannabis users 
may not be generalizable to all clinical samples seeking treatment. Consumption was 
measured over the past week. Monthly consumption would have provided a more robust 
assessment in this population and added confidence in the results. Cross-sectional data and 
the temporal nature of variables limit casual inferences. Further prospective studies are 
required to determine the influences of cannabis expectancies on consumption, dependence 
severity and mental health functioning over time. 
In summary, the CEQ is the first cannabis expectancy measure to be validated in a 
sample of cannabis users in treatment. The psychometric characteristics of the scale are 
strong with demonstrated construct validity and internal reliability across negative and 
positive cannabis expectancy domains. The CEQ factors were uniquely associated with 
consumption, dependence severity and self-reported mental health functioning.  
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Figure Captions 
 
Figure 1. Two-factor cannabis expectancy measurement model. 
Note. Ellipses represent latent constructs, and rectangles indicate measured variables. Circles (e) reflect 
residuals. Standardized maximum likelihood parameters are presented. All parameters are significant at p < .05 
unless otherwise indicated. 
†
p = .05. 
 
 
Table 1 
Descriptive Statistics for EFA Sample (N = 501; nmales = 390; nfemales = 111) 
 Mean S.D. 
Age (years) 27.45  8.19 
Weekly cannabis use (gms)
a
 3.53 5.07 
Severity of Dependence Scale (SDS)
b
 3.24 3.27 
Past-month alcohol consumption (days)
c
 6.67 8.32 
Past-month alcohol consumption (grams/day)
d
 82.37 91.08 
a
n = 401; 
b
n = 306; 
c
n = 454; 
d
n = 462. 
Note. SDS score of 2 is the established dependence cut-off (Swift et al., 1998). 
 
Table 2 
Item loadings from principal components analysis (PCA) of the Cannabis Expectancy 
Questionnaire (N = 501) 
Item 
Negative 
Expectancy 
Positive 
Expectancy 
44. Smoking cannabis makes me feel insecure .75  
50. When I smoke cannabis I feel “panicky” .70  
31. Smoking cannabis makes me more easily irritated .69  
22. When I smoke cannabis I withdraw from others .69  
38. When I am smoking cannabis I avoid people or situations for 
fear of embarrassment .68  
12. Smoking cannabis makes me confused .67  
24. Smoking cannabis increases my tension .67  
49. Cannabis makes me feel more jumpy and agitated .67  
53. When smoking cannabis my feelings rapidly shift from one to 
another .66  
17. I am more depressed when smoking cannabis .66  
55. When smoking cannabis people find it difficult to understand 
me .66  
45. When smoking cannabis I do things that I do not really mean 
to do .65  
26. When I smoke cannabis I find it hard to get certain thoughts 
out of my head 
.65  
60. When smoking cannabis I feel out of touch with reality .64  
40. I am disappointed in myself when smoking cannabis .63  
42. I am clumsier when smoking cannabis .61  
35. When I smoke cannabis my mood feels flat .61  
16. I feel restless when smoking cannabis .59  
6. Smoking cannabis makes me feel tense .58  
52. When smoking cannabis I have thoughts that are not my own .56  
28. When I smoke cannabis I feel less motivated .55  
4. I am more worried about what others are saying about me 
when I am smoking cannabis 
.54  
19. Smoking cannabis makes me feel sluggish .53  
30. I tend to adopt a “who cares” attitude when smoking 
cannabis 
.49  
48. I lose most feelings of sexual interest after I have been 
smoking cannabis 
.46  
41. I tend to avoid sex if I have been smoking cannabis .46  
8. I have bizarre or strange thoughts when smoking cannabis .44  
7. I have more self-confidence when smoking cannabis  .70 
9. I smoke cannabis to get full enjoyment out of life  .68 
33. I feel less shy if I have been smoking cannabis  .67 
23. When I smoke cannabis it is easier to express my feelings  .67 
43. Cannabis helps me to get along with others  .66 
5. Smoking cannabis makes me feel outgoing and friendly  .65 
39. When I smoke cannabis I can speak my mind  .65 
54. Smoking cannabis gives me more energy  .64 
37. Smoking cannabis helps me concentrate  .61 
36. Smoking cannabis makes me happy  .61 
1. I get better ideas when smoking cannabis  .61 
47. I have more energy when smoking cannabis  .60 
10. Smoking cannabis makes me more sexually responsive  .59 
34. Smoking cannabis helps me to feel “normal” again  .59 
51. Smoking cannabis makes me feel excited  .59 
14. I am more aware of what I say and do when I am smoking 
cannabis 
 .52 
3. Little things annoy me less when I am smoking cannabis  .48 
29. Smoking cannabis makes me laugh  .34 
   
Cronbach‟s α .94 .90 
% variance 23.30 15.83 
Mean  
(Standard Deviation) 
63.75 
(17.78) 
48.80 
(11.55) 
Note. Item loadings lower than .30 not shown for clarity of exposition. 
 
Table 3 
Descriptive Statistics for CFA Sample (n = 505; nmales = 393; nfemales = 112) 
 Mean S.D. 
Age (years) 27.69  8.72 
Weekly cannabis use (gms)
a
 3.90 5.69 
Severity of Dependence Scale
b
 3.32 3.20 
Past-month alcohol consumption (days)
c
 7.61 8.66 
Past-month alcohol consumption (grams/day)
d
 88.13 158.17 
CEQ Negative Expectancy 63.38 16.33 
CEQ Positive Expectancy 50.15 10.34 
GHQ Somatic Symptoms 0.90 1.47 
GHQ Anxiety 1.07 1.75 
GHQ Social Dysfunction
e
 0.83 1.61 
GHQ Depression
e
 1.35 3.54 
a
n = 424; 
b
n = 331; ; 
c
n = 474; 
d
n = 471; 
e
n = 504. 
# Note. SDS score of 2 is the established dependence cut-off (Swift et al., 1998) 
 

Table 4 
Fit Indices for Confirmatory Factor Analyses (N = 505; nmales = 393; nfemales = 112) 
Model χ2 (df) Bollen-Stine bootstrap p CFI SRMR RMSEA AIC ΔAIC 
Full Sample        
 1. Hypothesized measurement model 116.09* (26) .001 .98 .05 .08 154.09  
 2. One-factor expectancy model 1396.70* (27) .001 .62 .26 .32 1432.70  
 Difference between  
 Model 2 & Model 1 
      1278.61 
Gender Multi-Group Analysis        
 3. Hypothesized measurement model 155.94* (52) .001 .97 .04 .06 231.94  
 4. One-factor expectancy model 1431.57* (54) .001 .62 .25 .23 1503.57  
 Difference between  
 Model 4 & Model 3 
      1271.63 
Note. CFI = Comparative Fit Index; SRMR = Standardised Root Mean-Square Residual; RMSEA = Root Mean-Square Error of Approximation; AIC = Akaike  
* p < .05
 Table 5 
Summary of Hierarchical Regression Analysis for Cannabis Expectancies Predicting Weekly Cannabis Use and Cannabis Dependence Severity 
(N = 424) 
 Weekly Cannabis Use Dependence Severity 
Variable B SE B  B SE B  
Step 1       
 Age -0.04 0.03  -0.05 0.02*  
 Sex 0.71 0.66  -0.58 0.43  
Step 2       
 Age -0.04 0.03  -0.04 0.02  
 Sex 0.75 0.66  -0.44 0.41  
 Negative Expectancy (NE) 0.00 0.02  0.05 0.01***  
 Positive Expectancy (PE) 0.09 0.17***  0.02 0.02  
Step 3       
 Age -0.04 0.03  -0.04 0.02  
 Sex 0.75 0.66  -0.45 0.41  
 NE 0.00 0.02  0.05 0.01***  
 PE 0.10 0.03**  0.02 0.02  
 NE x PE 0.04 0.24  0.10 0.15  
*p < .05. **p < .01. ***p < .001. 
 
Weekly cannabis use: R
2
 = .01 for Step 1 (p = .32); ΔR2 = .03 for Step 2 (p = .001); ΔR2 = .00 (p = .88). 
 
Severity of Dependence. R
2
 = .02 for Step 1 (p = .03); ΔR2 = .06 for Step 2 (p < .001); ΔR2 = .00 (p = .51). 
 
 
 
 Table 6 
 
Summary of Hierarchical Regression Analysis for Cannabis Expectancies Predicting GHQ scores (n = 326) 
 
 Somatic Symptoms Anxiety Social 
Dysfunction 
 Depression 
Variable B SE B  B SE B  B SE B  B SE B  
Step 1             
  Weekly cannabis use (gms) 0.01 0.01  0.03 0.02  0.02 0.02  0.01 0.01  
  Severity of Dependence 0.05 0.03  0.06 0.03*  0.10 0.03***  0.04 0.02  
Step 2             
  Weekly cannabis use (gms) 0.01 0.02  0.03 0.02  0.02 0.02  0.01 0.01  
  Severity of Dependence 0.04 0.03  0.06 0.03  0.09 0.03**  0.04 0.02  
  Negative Expectancy (NE) 0.01 0.01  0.00 0.01  0.01 0.01*  0.02 0.01  
  Positive Expectancy (PE) 0.00 0.01  0.00 0.01  0.00 0.01  0.01 0.01*  
Step 3             
  Weekly cannabis use (gms) 0.01 0.02  0.03 0.02  0.01 0.02  0.01 0.01  
  Severity of Dependence 0.03 0.03  0.06 0.03  0.08 0.03**  0.03 0.02  
  NE 0.01 0.01*  0.01 0.01  0.02 0.01*  0.00 0.01  
  PE 0.01 0.01  0.02 0.01  0.02 0.01  0.03 0.01***  
  NE x PE 0.20 0.07**  0.22 0.08**  0.27 0.08***  0.25 0.06***  
*p < .05. **p < .01. ***p < .001. 
 
Somatic Symptoms: R
2
 = .01 for Step 1 (p = .10); ΔR2 = .01 for Step 2 (p = .25); ΔR2 = .02 for Step 3 (p = .01). 
 
Anxiety:  R
2
 = .03 for Step 1 (p = .01); ΔR2 = .00 for Step 2 (p = .84); ΔR2 = .02 for Step 3 (p = .01). 
 
Social Dysfunction: R
2
 = .05 for Step 1 (p < .001); ΔR2 = .01 for Step 2 (p = .14); ΔR2 = .04 for Step 3 (p < .001). 
 
Depression: R
2
 = .02 for Step 1 (p = .07); ΔR2 = .02 for Step 2 (p = .08); ΔR2 = .05 for Step 3 (p < .001) 
 
 
  
Figure 1. Two-factor cannabis expectancy measurement model. 
Note. Ellipses represent latent constructs, and rectangles indicate measured variables. Circles (e) reflect residuals. Standardized maximum likelihood parameters are 
presented. All parameters are significant at p < .05 unless otherwise indicated. 
†
p = .05. 
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